SCHEMBL5125318

SCHEMBL5125318

NC(=O)c1nc(Cc2cc(Cl)ccc2OCc2ccccc2F)cs1

nearest known ligand 0.63

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
PTGER1 P34995 11/20 0.63
CYP1A2 P05177 2/20 0.53
CYP2C9 P11712 2/20 0.53
TBXA2R P21731 2/20 0.53
PTGS1 P23219 2/20 0.53
CYP2C19 P33261 2/20 0.53
PTGER3 P43115 2/20 0.53
PTGER2 P43116 2/20 0.53
FNTA P49354 1/20 0.48
FNTB P49356 1/20 0.48
MEN1 O00255 1/20 0.47
PKM P14618 1/20 0.47
KMT2A Q03164 1/20 0.47
LMNA P02545 1/20 0.46
MAPT P10636 1/20 0.46
SMN1; SMN2 Q16637 1/20 0.46
NPSR1 Q6W5P4 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14098763 0.91 PTGER1 (0.66) PTGER1CYP1A2CYP2C9TBXA2RPTGS1
SCHEMBL5121253 0.90 PTGER1 (0.76) PTGER1CYP1A2CYP2C9TBXA2RPTGS1
SCHEMBL4720499 0.90 PTGER1 (0.64) PTGER1CYP1A2CYP2C9TBXA2RPTGS1
SCHEMBL5124977 0.89 PTGER1 (0.62) PTGER1CYP1A2CYP2C9TBXA2RPTGS1
SCHEMBL5125799 0.89 PTGER1 (0.57) PTGER1CYP1A2CYP2C9TBXA2RPTGS1
SCHEMBL4720358 0.86 PTGER1 (0.56) PTGER1CYP1A2CYP2C9TBXA2RPTGS1
SCHEMBL5129638 0.86 PTGER1 (0.62) PTGER1CYP1A2CYP2C9TBXA2RPTGS1
SCHEMBL5123553 0.85 PTGER1 (0.62) PTGER1CYP1A2CYP2C9TBXA2RPTGS1
SCHEMBL5119772 0.84 PTGER1 (0.70) PTGER1MEN1KMT2ASMN1; SMN2
SCHEMBL14098762 0.81 PTGER1 (0.68) PTGER1CYP1A2CYP2C9TBXA2RPTGS1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080207708-A1 Oxazole and Thiazole Compounds and Their Use in the Treatment of Pge2 Mediated Disorders GLAXO GROUP LIMITED (GB) 2008-08-28 US disclosed
US-20080207708-A1 Oxazole and Thiazole Compounds and Their Use in the Treatment of Pge2 Mediated Disorders GLAXO GROUP LIMITED (GB) 2008-08-28 US disclosed
US-20080207708-A1 Oxazole and Thiazole Compounds and Their Use in the Treatment of Pge2 Mediated Disorders GLAXO GROUP LIMITED (GB) 2008-08-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080207708-A1 Oxazole and Thiazole Compounds and Their Use in the Treatment of Pge2 Mediated Disorders PTGER1, PTGER2, PTGER4 PTGER1 1/4885CYP1A2 61/4885CYP2C9 142/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.